ACP
KROS icon

Acuta Capital Partners’s Keros Therapeutics KROS Stock Holding History

Acuta Capital Partners’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,575
Closed -$153K – 38
2023
Q1 		$153K Sell
3,575
-76,425
-96% -$3.86M 0.11% 32
2022
Q4 		$3.84M Buy
+80,000
New +$3.74M 2.36% 19

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Acuta Capital Partners's KROS Position: Q2 2023 in Review

Acuta Capital Partners sold out of Keros Therapeutics (KROS) in Q2 2023, closing a stake of 3,575 shares — an estimated $153K sold.

Acuta Capital Partners first reported a position in KROS in Q4 2022 and held it in 2 quarters. The position peaked at $3.84M in Q4 2022. 123 funds tracked by Wall St. Rank hold KROS as of Q2 2023.

  • Acuta Capital Partners reported no remaining Keros Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Acuta Capital Partners sold 3,575 Keros Therapeutics shares in Q2 2023, an estimated $153K.
  • Acuta Capital Partners first reported a position in Keros Therapeutics in Q4 2022 and held it in 2 quarters.
  • Acuta Capital Partners's Keros Therapeutics position peaked at $3.84M in Q4 2022.
  • 123 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2023.

Based on Acuta Capital Partners's 13F filing for Q2 2023, filed 14 Aug 2023.